Amicus Therapeutics Inc: (NASD: FOLD)
$2.54
-0.65 (-20.38%)
Volume 3,030,943
Jun 17 03:59 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 2.30 - 2.63 |
| 52wk Low - High | 2.30 - 6.89 |
| Previous Close | 3.19 |
| Avg. Volume | 297,532 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 158.33 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.94 |
| P/E (F1) | 0.00 |
| Current Year Est. | -1.35 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
102 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.35 |
| Current Quarter Estimate | -0.32 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-06-2013 |
| EPS Last Year | -1.12 |
| Expected Earnings Growth | NA |
Company Description
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.32 | -0.34 | -1.35 | -1.26 |
| Number of Estimates | 4 | 4 | 4 | 4 |
| Low Estimate | -0.35 | -0.37 | -1.44 | -1.67 |
| High Estimate | -0.28 | -0.29 | -1.21 | NA |
| Year Ago EPS | -0.20 | -0.35 | -1.08 | -1.35 |
| EPS Growth | -62.50% | 4.29% | -25.00% | 6.85% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AMICUS THERAPT | FOLD | 3.19 | |
|
| AETERNA ZENTARS | AEZS | 1.93 | |
|
| ANIKA THERAPEUT | ANIK | 15.68 | |
|
| BIOGEN IDEC INC | BIIB | 211.99 | |
|
| MYRIAD GENETICS | MYGN | 27.59 | |
|
| PROTALIX BIOTHR | PLX | 4.98 | |
|
| ADDEX THERA LTD | ADDXF | 4.36 | |
|
| AFFYMAX INC | AFFY | 1.10 | |
|
| ALEXION PHARMA | ALXN | 92.22 | |
|
| ALNYLAM PHARMA | ALNY | 30.11 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Glaxo's Influenza Vaccine Approved
Dec 24, 2012
Glaxo/Amicus' Fabry Drug Disappoints
Dec 21, 2012
Glaxo's Anthrax Drug Gets FDA Nod
Dec 18, 2012
Glaxo Invests in Nigeria
Nov 28, 2012
Glaxo to Expand in India
Nov 27, 2012
Glaxo's Promacta Label Expanded
Nov 20, 2012
Glaxo Misses on Both Counts
Nov 01, 2012
The Zacks Analyst Blog Highlights: GlaxoSmithKline, Pfizer, Theravance, Amicus Therapeutics and Parker-Hannifin
Oct 09, 2012
Financials
| EPS TTM | -1.12 |
| Sales | 18 |
| Net Income | -53 |
| Price/Earnings | NA |
| Price/Book | 2.97 |
| Price/Cash Flow | NA |
| Price/Sales | 5.31 |
News
Afternoon Market Losers - Benzinga
Jun 17, 2013
Amicus Delays U.S. Approval Filing for Fabry Disease Drug - TheStreet.com
Jun 17, 2013
Amicus Therapeutics to Discuss Regulatory Strategy on 8:00 AM ET Conference Call - Benzinga
Jun 17, 2013
Amicus Therapeutics to Host Conference Call Today at 8:00 a.m. ET to Discuss Regulatory Strategy for Migalastat HCl Monotherapy for Fabry Disease - Globenewswire
Jun 17, 2013
Hot Stock: Amicus Therapeutics, Shares Drop 21.2% (FOLD) - Comtex Smartrend(R)
Jun 17, 2013
Hot Stock: Amicus Therapeutics, Shares Drop 21.2% (FOLD) - Financial News Network Online - Market Movers
Jun 17, 2013
Market Wrap for Tuesday, June 17: Stocks Jump to Start Trading Week; Dow Rallies Triple Digits - Benzinga
Jun 17, 2013
Morning Market Losers - Benzinga
Jun 17, 2013
Broker Recommendations
| Current ABR | 1.86 |
| ABR (Last Week) | 2.00 |
| # of recs in ABR | 7 |
| Average Target Price | 4.70 |
| Industry Rank by ABR | 102 out of 265 |
| Rank in Industry | 30 out of 153 |
